<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03120676</url>
  </required_header>
  <id_info>
    <org_study_id>17-191</org_study_id>
    <nct_id>NCT03120676</nct_id>
  </id_info>
  <brief_title>Study of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma</brief_title>
  <official_title>A Phase II Study of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study with the purpose of studying the safety and efficacy of the study drug&#xD;
      Atezolizumab in patients with relapsed or refractory Hodgkin lymphoma (HL). Atezolizumab&#xD;
      could shrink cancer but it could also cause side effects. This study will also test any good&#xD;
      and bad effects the study drug. Other aims include studying biomarkers that will help&#xD;
      researchers understand how the drug works.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of accrual&#xD;
  </why_stopped>
  <start_date type="Actual">April 14, 2017</start_date>
  <completion_date type="Actual">November 12, 2018</completion_date>
  <primary_completion_date type="Actual">November 12, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is a protocol comprised of a single institution phase II study in HL evaluating the efficacy of atezolizumab.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>12 months</time_frame>
    <description>The primary endpoint will be computed as proportions along with exact 95% confidence intervals.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Atezolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment will be Atezolizumab administered at 1200 mg IV every 3 weeks. A cycle is defined as 3 weeks of therapy. Therapy will continue until disease progression, intolerable toxicities or death for a maximum duration of treatment of 36 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>All patients will receive atezolizumab 1200 mg via IV infusion on D1 of each 21-day cycle.</description>
    <arm_group_label>Atezolizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed Informed Consent Form (ICF)&#xD;
&#xD;
          -  Ability and willingness to comply with the requirements of the study protocol&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Patient has histologically confirmed diagnosis of Hodgkin lymphoma&#xD;
&#xD;
          -  Patients must have received at least 2 prior regimens and have received or be deemed&#xD;
             ineligible for autologous stem cell transplant, and must have received prior&#xD;
             brentuximab vedotin.&#xD;
&#xD;
          -  Patients who received prior anti-PD-1 therapy are eligible for cohort 1 only and&#xD;
             patients who have not received prior anti-PD-1 therapy are eligible for cohort 2 only.&#xD;
&#xD;
          -  Patient has at least one measurable nodal lesion (≥ 2 cm) according to RECIL Criteria&#xD;
&#xD;
          -  Adequate hematologic and end organ function, defined by the following laboratory&#xD;
             results obtained within 14 days prior to the first study treatment (Cycle 1, Day 1):&#xD;
&#xD;
               -  ANC ≥ 1500 cells/µL&#xD;
&#xD;
               -  WBC counts &gt; 2500/µL&#xD;
&#xD;
               -  Lymphocyte count ≥ 300/µL&#xD;
&#xD;
               -  Hemoglobin ≥ 9.0 g/dL&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5 x upper limit of normal (ULN) with the following exception:&#xD;
&#xD;
               -  Patients with known Gilbert disease who have serum bilirubin level ≤ 3 x ULN may&#xD;
                  be enrolled.&#xD;
&#xD;
               -  AST and ALT ≤ 3.0 x ULN with the following exception:&#xD;
&#xD;
               -  Patients with liver involvement: AST and/or ALT ≤ 5 x ULN&#xD;
&#xD;
               -  Alkaline phosphatase ≤ 2.5 x ULN with the following exception:&#xD;
&#xD;
               -  Patients with documented liver involvement or bone metastases: alkaline&#xD;
                  phosphatase ≤ 5 x ULN&#xD;
&#xD;
               -  Serum creatinine ≤ 1.5 x ULN or creatinine clearance ≥ 50 mL/min on the basis of&#xD;
                  the Cockcroft-Gault glomerular filtration rate estimation:&#xD;
&#xD;
               -  (140 - age) x (weight in kg) x (0.85 if female) 72 x (serum creatinine in mg/dL)&#xD;
&#xD;
          -  For female patients of childbearing potential and male patients with partners of&#xD;
             childbearing potential, agreement (by patient and/or partner) to use highly effective&#xD;
             form(s) of contraception (i.e., one that results in a low failure rate [&lt;1% per year]&#xD;
             when used consistently and correctly) and to continue its use for 90 days after the&#xD;
             last dose of Atezolizumab&#xD;
&#xD;
          -  Female subject of childbearing potential should have a negative serum pregnancy within&#xD;
             28 days prior to receiving the first dose of study medication.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have undergone prior allogeneic transplant are excluded only if they&#xD;
             remain on any immunosuppression or have signs or symptoms of clinical&#xD;
             graft-versus-host disease&#xD;
&#xD;
          -  Any approved anticancer therapy, including chemotherapy, hormonal therapy, or&#xD;
             radiotherapy, within 3 weeks prior to initiation of study treatment.&#xD;
&#xD;
          -  Herbal therapy (including herbal therapy intended as anticancer therapy) &lt; 1 week&#xD;
             prior to Cycle 1, Day 1&#xD;
&#xD;
          -  AEs from prior anticancer therapy that have not resolved to Grade ≤ 1 except for&#xD;
             alopecia&#xD;
&#xD;
          -  Known clinically significant liver disease&#xD;
&#xD;
          -  Active viral, alcoholic, or other hepatitis; cirrhosis; fatty liver; and inherited&#xD;
             liver disease&#xD;
&#xD;
          -  Pregnancy, lactation, or breastfeeding&#xD;
&#xD;
          -  Known hypersensitivity to Chinese hamster ovary cell products or other recombinant&#xD;
             human antibodies&#xD;
&#xD;
          -  Inability to comply with study and follow-up procedures&#xD;
&#xD;
          -  History or risk of autoimmune disease, including but not limited to systemic lupus&#xD;
             erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis&#xD;
             associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's&#xD;
             syndrome, Bell's palsy, Guillain-Barré syndrome, multiple sclerosis, autoimmune&#xD;
             thyroid disease, vasculitis, or glomerulonephritis&#xD;
&#xD;
          -  Patients with a history of autoimmune hypothyroidism AND without normal thyroid&#xD;
             hormone levels on a stable dose of thyroid replacement hormone&#xD;
&#xD;
          -  Myocardial infarction or arterial thromboembolic events within 6 months prior to&#xD;
             baseline or severe or unstable angina, New York Heart Association (NYHA) Class III or&#xD;
             IV disease, or a QTc interval &gt; 470 msec.&#xD;
&#xD;
          -  History of Torsades de pointes, ventricular tachycardia, or ventricular fibrillation&#xD;
&#xD;
          -  Uncontrolled heart failure or hypertension or uncontrolled diabetes mellitus&#xD;
&#xD;
          -  Patients with uncontrolled eczema, psoriasis, lichen simplex chronicus of vitiligo&#xD;
             with dermatologic manifestations (patients without ophthalmologic involvement, rash&#xD;
             covering &lt;10% of the body surface area and requiring only low potency topical&#xD;
             steroids, and without exacerbations requiring systemic therapy are eligible.)&#xD;
&#xD;
          -  History of idiopathic pulmonary fibrosis, pneumonitis (including drug induced),&#xD;
             organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing&#xD;
             pneumonia, etc.), or evidence of active pneumonitis on screening chest computed&#xD;
             tomography (CT) scan.&#xD;
&#xD;
          -  A history of radiation pneumonitis in the radiation field (fibrosis) is permitted&#xD;
             provided that symptoms have resolved.&#xD;
&#xD;
          -  Any other diseases, metabolic dysfunction, physical examination finding, or clinical&#xD;
             laboratory finding giving reasonable suspicion of a disease or condition that&#xD;
             contraindicates the use of an investigational drug or that may affect the&#xD;
             interpretation of the results or render the patient at high risk from treatment&#xD;
             complications&#xD;
&#xD;
          -  History of HIV infection or active hepatitis B (chronic or acute) or hepatitis C&#xD;
             infection&#xD;
&#xD;
               -  Patients with past or resolved hepatitis B infection (defined as having a&#xD;
                  negative hepatitis B surface antigen [HBsAg] test and a positive anti-HBc&#xD;
                  [antibody to hepatitis B core antigen] antibody test) are eligible.&#xD;
&#xD;
               -  Patients positive for hepatitis C virus (HCV) antibody are eligible only if&#xD;
                  polymerase chain reaction (PCR) is negative for HCV RNA.&#xD;
&#xD;
          -  Patients with active tuberculosis&#xD;
&#xD;
          -  Severe infections within 4 weeks prior to Cycle 1, Day 1, including but not limited to&#xD;
             hospitalization for complications of infection, bacteremia, or severe pneumonia&#xD;
&#xD;
          -  Signs or symptoms of infection within 2 weeks prior to Cycle 1, Day 1&#xD;
&#xD;
          -  Received oral or IV antibiotics within 2 weeks prior to Cycle 1, Day 1 for treatment&#xD;
             of active infection (Patients receiving prophylactic antibiotics (e.g., for prevention&#xD;
             of a urinary tract infection or chronic obstructive pulmonary disease) are eligible)&#xD;
&#xD;
          -  Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract&#xD;
             infection or chronic obstructive pulmonary disease) are eligible.&#xD;
&#xD;
          -  Major surgical procedure within 28 days prior to Cycle 1, Day 1 or anticipation of&#xD;
             need for a major surgical procedure during the course of the study&#xD;
&#xD;
          -  Administration of a live, attenuated vaccine within 4 weeks before Cycle 1, Day 1 or&#xD;
             anticipation that such a live, attenuated vaccine will be required during the study&#xD;
&#xD;
          -  Malignancies other than the disease under study within 5 years prior to Cycle 1, Day&#xD;
             1, with the exception of those with a negligible risk of metastasis or death and with&#xD;
             expected curative outcome (such as adequately treated carcinoma in situ of the cervix,&#xD;
             basal or squamous cell skin cancer, localized prostate cancer treated surgically with&#xD;
             curative intent, or ductal carcinoma in situ treated surgically with curative intent)&#xD;
             or undergoing active surveillance per standard-of-care management (e.g., chronic&#xD;
             lymphocytic leukemia Rai Stage 0, prostate cancer with Gleason score ≤ 6, and&#xD;
             prostate-specific antigen [PSA] ≤ 10 mg/mL, etc.)&#xD;
&#xD;
        Medication-Related Exclusion Criteria:&#xD;
&#xD;
          -  Prior anti-PD-L1 therapies are excluded.&#xD;
&#xD;
             °Patients who have received prior treatment with immunotherapy including anti-PD-1&#xD;
             anti-CTLA-4 may be enrolled, provided that there was no history of severe&#xD;
             immune-related adverse effects (NCI CTCAE Grade 3 and 4)&#xD;
&#xD;
          -  Treatment with investigational agent within 4 weeks prior to Cycle 1, Day 1 (or within&#xD;
             five half-lives of the investigational product, whichever is longer)&#xD;
&#xD;
          -  Treatment with systemic immunosuppressive medications (including but not limited to&#xD;
             prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor&#xD;
             necrosis factor [anti-TNF] agents) within 2 weeks prior to Cycle 1, Day 1&#xD;
&#xD;
               -  Patients who have received acute, low-dose, systemic immunosuppressant&#xD;
                  medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled.&#xD;
&#xD;
               -  The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone)&#xD;
                  for patients with orthostatic hypotension or adrenocortical insufficiency is&#xD;
                  allowed.&#xD;
&#xD;
          -  History of severe allergic, anaphylactic, or other hypersensitivity reactions to&#xD;
             chimeric or humanized antibodies or fusion proteins&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anas Younes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Basking Ridge</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Monmouth</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Commack</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Westchester</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Rockville Centre</name>
      <address>
        <city>Rockville Centre</city>
        <state>New York</state>
        <zip>11570</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/mskcc/html/44.cfm</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>April 17, 2017</study_first_submitted>
  <study_first_submitted_qc>April 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2017</study_first_posted>
  <results_first_submitted>October 25, 2019</results_first_submitted>
  <results_first_submitted_qc>November 12, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 14, 2019</results_first_posted>
  <last_update_submitted>November 12, 2019</last_update_submitted>
  <last_update_submitted_qc>November 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relapsed</keyword>
  <keyword>Refractory</keyword>
  <keyword>Atezolizumab</keyword>
  <keyword>17-191</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 17, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/76/NCT03120676/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Atezolizumab</title>
          <description>Treatment will be Atezolizumab administered at 1200 mg IV every 3 weeks. A cycle is defined as 3 weeks of therapy. Therapy will continue until disease progression, intolerable toxicities or death for a maximum duration of treatment of 36 cycles.&#xD;
Atezolizumab: All patients will receive atezolizumab 1200 mg via IV infusion on D1 of each 21-day cycle.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not treated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Atezolizumab</title>
          <description>Treatment will be Atezolizumab administered at 1200 mg IV every 3 weeks. A cycle is defined as 3 weeks of therapy. Therapy will continue until disease progression, intolerable toxicities or death for a maximum duration of treatment of 36 cycles.&#xD;
Atezolizumab: All patients will receive atezolizumab 1200 mg via IV infusion on D1 of each 21-day cycle.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33" lower_limit="28" upper_limit="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival</title>
        <description>The primary endpoint will be computed as proportions along with exact 95% confidence intervals.</description>
        <time_frame>12 months</time_frame>
        <population>Data not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Atezolizumab</title>
            <description>Treatment will be Atezolizumab administered at 1200 mg IV every 3 weeks. A cycle is defined as 3 weeks of therapy. Therapy will continue until disease progression, intolerable toxicities or death for a maximum duration of treatment of 36 cycles.&#xD;
Atezolizumab: All patients will receive atezolizumab 1200 mg via IV infusion on D1 of each 21-day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <description>The primary endpoint will be computed as proportions along with exact 95% confidence intervals.</description>
          <population>Data not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <desc>Only mortality data collected ,Serious and Other Adverse Events not monitored/assessed</desc>
      <group_list>
        <group group_id="E1">
          <title>Atezolizumab</title>
          <description>Treatment will be Atezolizumab administered at 1200 mg IV every 3 weeks. A cycle is defined as 3 weeks of therapy. Therapy will continue until disease progression, intolerable toxicities or death for a maximum duration of treatment of 36 cycles.&#xD;
Atezolizumab: All patients will receive atezolizumab 1200 mg via IV infusion on D1 of each 21-day cycle.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Anas Younes, MD</name_or_title>
      <organization>Memorial Sloan Kettering Cancer Center</organization>
      <phone>212-639-5059</phone>
      <email>younesa@mskcc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

